raised above the stimulatory threshold. This gradual decline suggests that the implanted oestradiol is eliminated from body tissues much more slowly than thought previously (figure). We emphasise that according to the recommendations in the Data Sheet Compendium our patients were not overdosed but were treated with a conventional regimen of 50 mg oestradiol implants reinserted roughly every six months. The mean oestradiol dose a year was 83 mg, which we would not consider to be excessive. Two of the three patients on whom data are available had plasma oestradiol values within the premenopausal range at the time of the last implant.
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Our main anxiety with long lasting implants is the long term risk of endometrial malignancy. Less than three years of treatment with oral, unopposed oestrogens increases the risk of endometrial cancer ninefold for two to 14 years after treatment is withdrawn.'0 We suspect that prolonged unopposed stimulation by oestrogen after discontinuation of implant treatment will increase the risk of endometrial neoplasia and hence progestogen needs to be added monthly for as long as withdrawal bleeding occurs. Even then endometrial hyperplasia may arise (cases 5 and 9). This could have been due to an inadequate progestogen dose or to poor compliance. Patients with implants who fail to comply strictly with taking progestogen are known to be at an increased risk of endometrial hyperplasia: one series reported an incidence of 56%. " Achieving good compliance with taking progestogen may be difficult. Symptomatic and psychological side effects are well recognised,4 and there can be few women who perceive a monthly withdrawal bleed as a blessing. Implant treatment in women with an intact uterus carries the possibility of a long term commitment to taking progestogen; clinicians should advise their patients to continue taking progestogen cyclically for as long as the withdrawal bleeding continues, not for a defined period of time such as four to eight months after the last implantation. times the number of markers in the abdomen and regional transit time as 1-2 times the number of markers in the region. In one patient with slow transit radiography was repeated on the sixth morning.
Whole gut transit time ranged from six to 108 hours. Stool frequency ranged from 0-3 to 5-0/24 h. There was no relation between stool frequency and whole gut transit time (r=-0 022). The mean stool form score was evenly distributed, with similar numbers of patients scoring <3, 3-5, and >5. Mean stool form score correlated well with whole gut transit time (r=-0 77, p<0001; figure). Although there were 7 6 0 **.. Relation between mean stool form score (I =hard lumps, 7 =watery; see text) and whole gut transit time in patients with irritable bowel svndrome (r -0 77, p<000I) significant correlations between regional colonic transit time and mean stool form score, no area of the colon was particularly associated with stool form (right colon, r=-0 43, p<0 05; left colon, r=-0 62, p<001; sigmoid and rectum, r=-0 54, p<0 01). Urgency was recorded at least once by 22 patients. Urgency was associated with looser stools (X) for trend=26, df=1, p<0001), but the frequency of defecation was the same in patients with and without urgency (median frequency=1l6 v 1-9/24 h; p=08, Mann-Whitney U test).
Comment
We found that patients with the irritable bowel syndrome can keep meaningful records of stool form and that these are a reasonable guide to whole gut BMJ VOLUME 300 17 FEBRUARY 1990
